EGFR and non-small cell lung carcinoma: In addition to cytotoxic chemotherapies, currently approved therapeutics for NSCLC include inhibitors of EGFR, ALK, ROS1, VEGF, and other proteins, as well as checkpoint blockade therapies targeting PD-1 and PD-L1 [2].